We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00056498
Recruitment Status : Completed
First Posted : March 17, 2003
Results First Posted : July 16, 2012
Last Update Posted : May 9, 2017
Information provided by (Responsible Party):

March 14, 2003
March 17, 2003
March 23, 2009
July 16, 2012
May 9, 2017
December 2001
December 2007   (Final data collection date for primary outcome measure)
Brief Psychiatric Rating Scale (BPRS) [ Time Frame: Measured at baseline and every 2 weeks for 16 weeks ]
Scale assesses psychotic symptoms on a 20-item scale. The severity of each item is rated on a continuous scale from 1-7, with 1 being the least severe and 7 being most severe.
Not Provided
Complete list of historical versions of study NCT00056498 on ClinicalTrials.gov Archive Site
Neuropsychological Testing [ Time Frame: Measured at baseline and Week 16 ]
Not Provided
Not Provided
Not Provided
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
Clozapine Treatment of Schizophrenic Patients
This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine.

Clozapine is the only antipsychotic drug that has been approved for treatment resistant patients with schizophrenia. However, up to 50% of patients treated with clozapine fail to respond and continue to exhibit clinically significant residual positive and negative symptoms and cognitive impairments. An emerging trend in treatment is the addition of a second antipsychotic drug. This study will determine if risperidone when given as adjunctive treatment is more effective than placebo in treating schizophrenic patients failing clozapine therapy.

Participants are randomly assigned to add either adjunctive risperidone or placebo to their current clozapine treatment in a single, daily dose for 16 weeks. Positive and negative symptoms, cognitive impairments, side effects of the treatment, anxiety, depression, hostility symptoms, and quality of life are assessed. Neurological tests, self administered questionnaires, and interviews are used to assess patients.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: Placebo
    Placebo capsule daily for 16 weeks
  • Drug: Risperdal
    Risperdal 4 mg per day for 16 weeks
    Other Name: Risperidone
  • Active Comparator: Active
    Participants assigned to risperidone
    Intervention: Drug: Risperdal
  • Placebo Comparator: Placebo
    Participants assigned to placebo
    Intervention: Drug: Placebo
Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology. 2010 Oct;35(11):2274-83. doi: 10.1038/npp.2010.101. Epub 2010 Jul 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2007
December 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • DSM-IV criteria for schizophrenia or schizoaffective disorder
  • Current clozapine treatment
  • Moderate illness severity and inadequate positive symptom response to clozapine treatment
  • 6 month period of clozapine treatment with documented clozapine blood level greater than or equal to 350 ng/ml or clozapine and norclozapine blood level greater than or equal to 450 ng/ml

Exclusion Criteria:

  • Organic brain disorder
  • Mental retardation
  • Medical condition whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol
  • Pregnancy
  • DSM-IV criteria for current alcohol or substance dependence within the last 6 months or DSM-IV criteria for alcohol or substance abuse within the last month
  • Previously received adjunctive risperidone (at doses greater than or equal to 8 mg/day) with their clozapine treatment for greater than or equal to 6 weeks
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
R01MH045074( U.S. NIH Grant/Contract )
R01MH045074 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
University of Maryland
University of Maryland
  • National Institute of Mental Health (NIMH)
  • Ortho-McNeil Janssen Scientific Affairs, LLC
Principal Investigator: Robert W Buchanan, MD University of Maryland
University of Maryland
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP